TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06118073

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Headspace
Description: Headspace is a smartphone-based application that guides individuals through various mindfulness sessions and has been shown to reduce symptoms of depression, anxiety, and pain. Participants will be required to answer questions regarding anxiety levels and pain for 6 weeks after surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Participant will have total knee replacement surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Participant will have total knee replacement surgery
Study: NCT06413771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Letrozole pretreatment during ovarian stimulation with gonadotropins, in intrauterine insemination cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin
Description: Ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
Study: NCT04922281

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Insertable Cardiac Monitor or external non-invasive LT-ECG patch
Description: Implantable device that provides accurate daily transmission. Patients without an existing CIED who prefer to use noninvasive LT-ECG monitoring will be offered to use the Carnation Ambulatory Monitor (CAM™; Bardy Diagnostics) the CAM™ patch approved for LT-ECG monitoring applied to the skin over the chest for a time-period of 7-days every 2 months for cardiac electrical data for arrhythmia detection.
Study: NCT05263843

Intervention type: DIAGNOSTIC_TEST
Intervention: Biological markers of myocardial fibrosis
Description: Blood sample for measurements of NET activation and collagen biomarkers
Study: NCT04922281

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertable Cardiac Monitor or external non-invasive LT-ECG patch
Description: Implantable device that provides accurate daily transmission. Patients without an existing CIED who prefer to use noninvasive LT-ECG monitoring will be offered to use the Carnation Ambulatory Monitor (CAM™; Bardy Diagnostics) the CAM™ patch approved for LT-ECG monitoring applied to the skin over the chest for a time-period of 7-days every 2 months for cardiac electrical data for arrhythmia detection.
Study: NCT05129709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Health Priorities Identification Program
Description: The web-based My Health Priorities Identification Program may improve values solicitation and operationalization skills in primary care, but has not been optimized for AAs with MCCs and their FCGs. The Program is a facilitator-led evidence- and values-based care communication model for patients, clinicians, and caregivers that has reduced patient-reported treatment burden by aligning value-based priorities with treatment. The web-based program assists patients in identifying their health priorities as they complete t four online modules that help them to identify specific and actionable health goals and preferences. The final result can be printed and brought to the clinic or uploaded to the Electronic Medical Record to inform subsequent healthcare decision making. Unrecognized cultural preferences of AAs, including the important role of R/S beliefs and family-centered values, can interfere with adequate healthcare communication resulting in healthcare disparities and inequities.
Study: NCT06735924

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-oxalate fixed diet
Description: Ingestion of a low-oxalate (\< 60 mg/day) , normal calcium (800-1200 mg/d) eucaloric diet for 5 days
Study: NCT06739928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome (II) combined with adebrelimab and carboplatin
Description: Irinotecan liposome (II) + adebrelimab + carboplatin
Study: NCT05427630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC ~2.5%
Description: Cannabis flower containing THC \~2.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC ~5%
Description: Cannabis flower containing THC \~5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC ~10%
Description: Cannabis flower containing THC \~5%

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Cannabis
Description: Cannabis flower from which the THC and CBD have been extracted
Study: NCT06035718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Blend Capsule
Description: By a probiotic blend capsule a specific product is intended which contains the following: Lactobacillus rhamnosus Lactobacillus plantarum Lactobacillus casei Lactobacillus helveticus Lactobacillus acidophilus Lactobacillus bulgaricus Lactobacillus gasseri Bifidobacterium bifidum Bifidobacterium lactis Bifidobacterium breve Bifidobacterium longum Streptococcus thermophile Fructooligosaccharides (FOS).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Using a tDCS device, a mild direct electric current is going to be non-invasively administered to the brain using rubber electrodes placed over the scalp.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Using a tDCS device, a mild direct electric current is going to be non-invasively administered to the brain using rubber electrodes placed over the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Using a tDCS device, a mild direct electric current is going to be non-invasively administered to the brain using rubber electrodes placed over the scalp. At this arm the electric current will be applied for a very short time (30 s) after which the device will turn off, thus providing the initial tingling sensation over the scalp but not interfering with the ongoing brain activity.
Study: NCT05465681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20013 for injection；dexamethason
Description: HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy.~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
Study: NCT06034730

Intervention type: DEVICE
Intervention: Portable GC device for brath analysis
Description: Patients were asked to orally exhale 1-2 L breath into a 5 L Tedlar bag via a one-way mouthpiece and Nafion filter for moisture removal, as shown in Figure 1B. The process usually takes about a few minutes. The breath analysis took place either in-situ immediately after the breath sample collection or within 24 h of breath collection. The Tedlar bags were stored under ambient condition until analyzed. During the breath analysis, the Tedlar bag was connected to the sampling port of the portable GC (Figure 1C). Approximately 350 mL of breath was pulled from the Tedlar bag into the GC for analysis. The GC operation was controlled using LabView via a laptop. The total assay time was 30 min, including 5 min of breath sampling time from the Tedlar bag at a flow rate of 70 mL/min (see the blue path in Figure 1A), 5 min of desorption/transfer time, 10 min of chromatographic separation time (see the orange path in Figure 1A), and 10 min of GC system cleaning time.
Study: NCT04053153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
Description: exercise equipment (a musical instrument that is based on the Medical Didgeridoo)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
Description: exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
Study: NCT05717322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TENS
Description: apply TENS after orthognathic surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sham TENS
Description: apply non active TENS after orthognathic surgery
Study: NCT04880317

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance
Description: All enrolled patients will undergo a contrast-enhanced CMR examination for the assessment of extracellular volume

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Additional CT acquisition
Description: All enrolled patients will undergo an additional CT scan at 5 minutes post-contrast injection to evaluate myocardial relative enhancement
Study: NCT05998239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bootle Boot Camp Home Exercise App - with Virtual Coach Botley
Description: Bootle Boot Camp exercise sessions offered with movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the no feedback condition for a period of 4 weeks (4 sessions/week). Movement feedback will be guided by skeletal data captured by the 3D motion tracking camera and based on predefined movement acceptability criteria for each exercise. Feedback will take the form of visual markers, text/audio cues and rewards.
Study: NCT06739928

Intervention type: DRUG
Group type: OTHER
Intervention: etoposide combined with adebrelimab and carboplatin
Description: etoposide + adebrelimab + carboplatin
Study: NCT04880317

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood tests
Description: Patients will undergo blood tests to review hematocrit, Sars-CoV-2 antibody status and cardiac fibrosis biomarkers
Study: NCT06332638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 12.5mg
Description: Oral administration of one tablet of Tegoprazan 12.5mg twice daily for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegoprazan 25mg
Description: Oral administration of one tablet of Tegoprazan 25mg once daily for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine 20mg
Description: Oral administration of one tablet of Famotidine 20mg twice daily for 14 days.
Study: NCT06516835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral fluid
Description: GNAK will be administered to the gastrointestinal tract with EN in the same volume.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous fluid
Description: Undiluted EN will be given to the gastrointestinal tract. GNAK, in the same volume, will be administered intravenously.
Study: NCT04949919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic training by a cycle ergometer and Biodex system 4 pro
Description: cyclic aerobic training in moderate-intensity and high-intensity interval training plus isokinetic resistance training prior to HD. 60 training sessions in 6 months.
Study: NCT05634356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vocal-social reinforcement
Description: experimental manipulation of social reinforcement in response to vocalizations
Study: NCT05998239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bootle Boot Camp Home Exercise App - without Virtual Coach Botley
Description: Bootle Boot Camp exercise sessions offered without movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the movement tracking feedback condition for a period of 4 weeks (4 sessions/week).
Study: NCT06738797

Intervention type: DIAGNOSTIC_TEST
Intervention: SPHERTEST test
Description: The SPHERETEST is an in vitro model of heterotypic spheroids composed of commercial urothelial carcinoma tumor cells and leukocyte mononuclear cells from healthy donors.
Study: NCT05943613

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clonidine
Description: compare the effect of intrathecal Clonidine and Neostigmine as adjuvants to Bupivacaine in elective cesarean section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: compare the effect of intrathecal Clonidine and Neostigmine as adjuvants to Bupivacaine in elective cesarean section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: compare the effect of intrathecal Clonidine and Neostigmine as adjuvants to Bupivacaine in elective cesarean section
Study: NCT03880461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Behavioral lifestyle intervention
Study: NCT04460937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT06737692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised Aerobic Exercises: Conducted every two weeks, three days a week (on days 11-13 post-systemic treatment). The supervised aerobic exercises will consist of 20 minutes on a treadmill at a heart rate corresponding to 55-75% of the Karvonen formula. Warm-up and cool-down will be performed at 30-40% of the Karvonen heart rate for 5 minutes.~Supervised Resistance Exercises: Conducted every two weeks on consecutive days (days 11 and 13 post-systemic treatment).~Resistance training will involve 12 different exercises targeting major muscle groups, using body weight and resistance bands, at an effort level of 5-7 on the Borg scale, with 8-12 repetitions and 1-3 sets. The intensity will be progressively adjusted based on the individual's perceived exertion.~On weeks without supervised exercises, participants will follow a home exercise program that includes breathing exercises, walking for 20-30 minutes, and resistance exercises.
Study: NCT05003245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection
Description: 0.05mL solution at a 4-week interval for intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: 0.05mL solution at a 4-week interval for intravitreal injection
Study: NCT04820985

Intervention type: OTHER
Intervention: Vaginal swab
Description: Vaginal flora swab 3 months before stimulation, at oocyte puncture, embryo transfer and beta-human chorionic gonadotropin dosing

Intervention type: OTHER
Intervention: Blood test
Description: Blood sample to measure plasma dose of progesterone
Study: NCT06463912

Intervention type: OTHER
Intervention: Does not apply
Description: A descriptive cross-sectional study will be carried out in the city of Armenia-Colombia. A total of 205 PWID, 18 years to 65 years old will be included. They will be selected through the implementation of the respondent-driven sampling (RDS).
Study: NCT05335122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TIC low dose Travoprost Intracameral Implant
Description: OTX-TIC implant is injected into the anterior chamber of the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TIC high dose Travoprost Intracameral Implant
Description: OTX-TIC implant is injected into the anterior chamber of the eye.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durysta, Bimatoprost Intracameral Implant 10 µg
Description: Durysta is injected into the anterior chamber of the eye.
Study: NCT04817540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herzuma
Description: 8mg/kg IVF loading dose at first cycle -\> 6mg/kg IVF at 2,3,4th cycle of each 21 day cycle
Study: NCT06738563

Intervention type: OTHER
Intervention: Collection breast milk
Description: Collection of a milk sample taken as part of women's donation
Study: NCT06741241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth Promotora
Description: Intervention participants attend an eHealth promotora-delivered educational session. Activities include an icebreaker, the completion of a baseline survey, an introduction to cervical cancer using a video and slide presentation, a cervical cancer knowledge pretest/posttest, and a dialogue activity to explore possible barriers and solutions to health care access. Main topics included in the slide presentation are: female anatomy; cervical cancer etiology and disease progression by stage; cancer prevention including diet, exercise, safe sex, cancer screening; human papillomavirus (HPV) vaccine recommendations; Pap test preparations, procedure, screening interval; and information about where to receive a Pap test and seek more information about cervical cancer.
Study: NCT06147375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus or Cyclosporine A
Description: The protocol of IS withdrawal:Week 1-4 take Tacrolimus (Tac) or Cyclosporine A (CsA) once daily for weeks. Week 5-8 medication reduction to taking Tac / CsA 4 times a week . Week 9-12 reduction to taking Tac/ CsA 3 times a week. Week 13-18 reduction to taking Tac / CsA 2 times a week . Week 19-24 reduction to taking Tac/ CsA once per week. Week 25, the recipients will stop taking Tac/ CsA.
Study: NCT06741241

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eHealth Healthy Nutrition
Description: Control group participants attend an eHealth educational session on healthy nutrition. Activities include an icebreaker, the completion of a baseline survey, an introduction to healthy eating using a video and a slide presentation, a cervical cancer knowledge pretest/posttest, and a dialogue activity to explore benefits and challenges to healthy eating.
Study: NCT06739018

Intervention type: OTHER
Intervention: pentacam scheimpflug tomography
Description: Pentacam tomography is not radiation-based. It uses Scheimpflug imaging, which involves a rotating camera that captures multiple images of the anterior segment of the eye. The system employs light-based technology to measure the front and back surfaces of the cornea, along with the anterior chamber and lens, creating a 3D model of the anterior eye structures.~it uses light instead of ionizing radiation (like X-rays), it is considered safe and non-invasive for routine use in ophthalmology.~* It was used to assess 23 parameters from topographic maps and 15 parameters from Belin-Ambrosio enhanced ectasia (BAD) display maps.~* Parameters included keratometry readings, anterior and posterior sagittal curvature, corneal thickness, anterior chamber volume, and several indices from the BAD display map.~* These parameters were analyzed to discriminate between keratoconus and high myopic astigmatism using Receiver Operating Characteristic (ROC) curves for diagnostic accuracy.
Study: NCT05370417

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Use of fluoride toothpaste
Description: The participants received oral hygiene instructions - routine brushing twice per day with toothpaste containing 1000 ppm of fluoride. All participants received a toothbrush and toothpaste to ensure standardization. The aim of this intervention was to assess whether the participants' brushing technique would improve with desensitization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of fluoride toothpaste
Description: The participants received oral hygiene instructions - routine brushing twice per day with toothpaste containing 1000 ppm of fluoride. All participants received a toothbrush and toothpaste to ensure standardization. The aim of this intervention was to assess whether the participants' brushing technique would improve with desensitization.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: For laser application, the following dosimetric parameters will be used:~Low level laser diode (infra red) wavelength 808nm with a power of 100mW. Three sessions: initial session, after 48 hours and after one month. LLL was applied to three perpendicular points in contact with the surface on the mesial vestibular and distal cervical faces and in the center of the occlusal face. An energy of 1 J was applied for 10 seconds at each point.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Simulated Laser Therapy
Description: The same application described in the laser therapy group will be simulated, with the device turned off.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sealant application
Description: A glass ionomer sealant will be applied to the occlusal surface of the first permanent molar.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sealant application
Description: A glass ionomer sealant will be applied to the occlusal surface of the first permanent molar.
Study: NCT05746455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation Skills Training (MST)
Description: MST is a weekly group-based skills training intervention that aims to improve knowledge about one's level and sources of motivation, the ability to monitor and regulate (understand and manage) motivation, so that one can better initiate and sustain goal-directed behavior.
Study: NCT05065281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Training for health care professionals on how to identify and manage cases of elder abuse among their patients
Study: NCT05362344

Intervention type: PROCEDURE
Intervention: Stool tests
Description: Non-invasive, stool-based tests for colorectal cancer screening.
Study: NCT04510597

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoreductive Nephrectomy
Description: Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Nephrectomy
Description: Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Nivolumab 240 mg IV 1 q 2 weeks~OR~Nivolumab 480 mg IV 1 q 4 weeks~OR~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID~OR~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID
Study: NCT04776798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping
Description: Tape applications will repeat twice per week, for 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Taping
Description: Tape applications will repeat twice per week, for 4 weeks.
Study: NCT04594577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluispotter
Description: Fluispotter automated blood sampling system applied for venous blood sampling of 20 10 μL samples in a 20 hours sampling session.